Core Viewpoint - BGI Genomics plans to acquire two companies for 366 million yuan, integrating spatiotemporal omics and nanopore sequencing assets to establish a comprehensive technology chain of "short-read long + long-read long + spatial omics," becoming the only life science company globally to cover these three major technologies, while also strengthening its "AI + life sciences + brain-computer interface" layout [1][7][12] Transaction Details - BGI Genomics intends to acquire 100% equity of Shenzhen BGI Sanjianqifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd. through cash transactions, with a total transaction price of 365.7 million yuan, comprising 158 million yuan for Sanjianqifa and 207.7 million yuan for Xufeng [3][10][12] - Following the acquisition of Sanjianqifa, BGI Genomics plans to increase its capital by 70 million yuan, with 22.15 million yuan allocated to registered capital and 47.85 million yuan to capital reserves [3][11] - After the acquisition of Xufeng, BGI Genomics plans to increase its capital by 60 million yuan, with 14.44 million yuan allocated to registered capital and 45.56 million yuan to capital reserves [4][11] Strategic Implications - The acquisition allows BGI Genomics to consolidate second-generation sequencing, long-read nanopore sequencing, and spatiotemporal omics technologies, completing a full technology chain and positioning itself as one of the few life science tool companies globally to cover this complete matrix [5][12] - This integration enhances the company's ability to provide independent and comprehensive solutions in upstream tools, broadening research and clinical application scenarios, and reshaping industry competition logic, transitioning from a single technology leader to a platform-based ecosystem leader [5][12]

Core Viewpoint - BGI Genomics plans to acquire two companies for 366 million yuan, integrating spatiotemporal omics and nanopore sequencing assets to establish a comprehensive technology chain of "short-read long + long-read long + spatial omics," becoming the only life science enterprise globally to cover these three major technologies, while also strengthening its layout in "AI + life sciences + brain-computer interfaces" [1][6]. Transaction Details - BGI Genomics intends to acquire 100% equity of Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd. through cash, with a total transaction price of 365.7 million yuan, where the equity of Sanjian Qifa is priced at 158 million yuan and that of BGI Xufeng at 207.7 million yuan [2][4]. Capital Increase Plans - After the acquisition of Sanjian Qifa, BGI Genomics plans to increase its capital by 70 million yuan, with 22.15 million yuan allocated to registered capital and 47.84 million yuan to capital reserves, ensuring that the funds are used for daily operations, business expansion, and payment for intellectual property rights [4][5]. - Following the acquisition of BGI Xufeng, BGI Genomics plans to increase its capital by 60 million yuan, with 14.44 million yuan allocated to registered capital and 45.56 million yuan to capital reserves, also ensuring that the funds are used for similar purposes [5]. Strategic Implications - The acquisition allows BGI Genomics to consolidate second-generation sequencing, nanopore long-read sequencing, and spatiotemporal omics technologies, completing a full technology chain from short-read to long-read and from sequence analysis to spatial dimensions, positioning the company among the few globally that cover this complete matrix in life science tools [6]. - This integration enhances the company's ability to provide autonomous and controllable upstream tools and one-stop solutions, broadening research and clinical application scenarios, and reshaping industry competition logic, facilitating a transition from single-point technology leadership to platform-based ecological dominance [6].